ARTICLE BY BIO X CELL

Bio X Cell Introduces First Commercially Available Anti-Mouse Trispecific Antibody for Preclinical Research

Bio X Cell has announced the launch of the first commercially available, ready-to-use anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody for preclinical research. Immuno-oncology workflows frequently require the evaluation of multiple immune pathways, which traditionally demands complex combination regimens. This newly introduced tetravalent trispecific antibody provides researchers with a refined in vivo tool to study combinatorial immune checkpoint biology within standard mouse models.

How Does the Trispecific Reagent Support Combinatorial Checkpoint Biology?

Checkpoint biology is inherently combinatorial, with multiple pathways regulating immune responses simultaneously. This anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody is designed to address this biological complexity through specific technical features:

• Simultaneous Multi-Pathway Interrogation: By bringing PD-L1, TIGIT, and LAG3 binding arms together into a single molecule, the format enables simultaneous analysis of three complementary pathways within one experimental system.

• Targeted Biological Insights: This configuration allows investigators to gracefully explore the distinct mechanisms of T-cell exhaustion and immune suppression in vivo.

• Bridging Immune Environments: The 2+2 tetravalent format is engineered to support the coordinated blockade of these inhibitory pathways, facilitating the bridging of tumor or antigen-presenting cells with T cells.

Why Use a Single Trispecific Format Over Multi-Agent Dosing?

When mapping overlapping immune checkpoints, managing traditional combination studies can present practical hurdles. Evaluating these interactions with a single trispecific reagent offers clear methodological advantages:

• Reduced Experimental Complexity: A single-molecule approach simplifies dosing protocols by eliminating the need to coordinate multi-agent cocktails.

• Minimized Data Variability: Utilizing one uniform format reduces the cohort-to-cohort variations and formulation differences that frequently accompany separate multi-agent dosing regimens.

• Streamlined Preclinical Workflows: This approach helps research teams maintain excellent continuity and design consistency from initial single-target validation through to sophisticated multispecific studies.

Engineered for Compatibility and In Vivo-Ready Quality

To support reliable integration into established preclinical workflows, the PD-L1 × TIGIT × LAG3 trispecific antibody has been developed with careful attention to structural compatibility and manufacturing standards:

• Murine IgG2a Constant Region: The antibody is recombinantly engineered with a mouse-specific IgG2a constant region to support natural compatibility with standard mouse models commonly utilized in immuno-oncology.

• Ultra-Pure Formulations: Prepared strictly to Bio X Cell’s rigorous in vivo-ready quality standards.

• Carrier-Free and Low Endotoxin: Carrier-free and maintained at low endotoxin levels, helping protect the biological signal from unintended experimental artifacts.